Home > Insider Trading > Filing (0000899243-20-013636)

Filing Details

Accession Number:: 0000899243-20-013636
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-05-19 20:46:32
Reporting Period:: 2020-05-13

Accepted Time:: 2020-05-19 20:46:32
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
730272	Repligen Corp	RGEN	Biological Products, (No Disgnostic Substances) (2836)	042729386

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1261506	A Karen Dawes	C/O Repligen Corporation 41 Seyon St., Bldg 1, Ste 100 Waltham MA 02453		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-05-13	722	$0.00	121,556	No	4	A	Direct
Common Stock	Disposition	2020-05-18	712	$135.76	120,844	No	4	S	Direct
Common Stock	Disposition	2020-05-18	160	$136.92	120,684	No	4	S	Direct
Common Stock	Disposition	2020-05-18	269	$138.60	120,415	No	4	S	Direct
Common Stock	Disposition	2020-05-18	122	$139.32	120,293	No	4	S	Direct
Common Stock	Disposition	2020-05-18	180	$140.62	120,113	No	4	S	Direct
Common Stock	Disposition	2020-05-18	77	$141.45	120,036	No	4	S	Direct
Common Stock	Disposition	2020-05-18	80	$142.45	119,956	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2020-05-13	1,761	$0.00	1,761	$128.18

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,761	2021-05-13	2030-05-13	No	4	A	Direct

Footnotes

Ms. Dawes was awarded 722 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 13, 2021. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on February 19, 2020.
$135.76 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.26 to $136.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$138.60 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.94 to $138.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$139.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.11 to $139.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$140.62 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.21 to $140.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$141.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.42 to $142.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Award vests in full one year from grant date on May 13, 2021.